Madrigal Pharmaceuticals, Inc.
MDGL · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $958M | $180M | +432% |
| Operating income | −$300M | −$498M | +39.7% |
| Net income | −$288M | −$466M | +38.1% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 3, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $431M | $287M | +50.1% |
| Operating income | $56.0M | −$114M | |
| Net income | $55.4M | −$114M |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Madrigal's revenue in FY2025?
- $958M in FY2025 (Fiscal year ended Dec 31, 2025), +432% vs $180M a year earlier, per its 10-K filed Feb 2026.
- Was Madrigal profitable in FY2025?
- No: net income was −$288M and operating income −$300M in FY2025.
- What was Madrigal's revenue in Q3 2026?
- $431M (+50.1% vs a year earlier), per its Form 10-Q filed Nov 3, 2026.